PDSB’s PDS01ADC Clinical Trial Yields 78% Response Rate in Tough-to-Treat Colorectal Cancer—Survival Nearly Doubles vs. Standard Approach
Early Data Highlight Substantial Improvement Over Existing Therapies
PDS Biotechnology Corporation (NASDAQ:PDSB) released interim data from Stage 1 of its Phase 2 clinical trial for PDS01ADC, a targeted immunocytokine, in patients with metastatic colorectal cancer (mCRC). According to results published in the Journal of Clinical Oncology, the addition of PDS01ADC led to an impressive 78% objective response rate (ORR) at six months—more than double the 35% response rate in a parallel trial that did not use the drug.
Survival Rates and Disease Progression Metrics Point to Major Step Forward
The benefits of PDS01ADC extended to overall survival. Patients receiving PDS01ADC achieved an estimated two-year survival rate of 85%, compared to around 40% in a similar group without the therapy. Crucially, the median extrahepatic progression-free survival (PFS) was not reached after just over a year of follow-up, while those outside the PDS01ADC group had a PFS of 8.1 months.
| Trial Group | Objective Response Rate | 2-Year Survival Rate | Median Extrahepatic PFS |
|---|---|---|---|
| PDS01ADC + HAIP (N=9) | 77.78% | 85% | Not reached (=13.1 mo.) |
| HAIP Only (Parallel Trial, N=20) | 35% | 40% | 8.1 mo. |
Clinical Context: Meeting an Unmet Need in Colorectal Cancer
These findings are significant, especially as the trial population included patients with unstable microsatellite status (MSS) or mismatch repair proficiency (pMMR)—a group known to be resistant to immune checkpoint inhibitors, making up about 95% of mCRC cases. Given that metastatic colorectal cancer remains the second leading cause of cancer-related death in the United States, incremental improvements in treatment outcomes are critical for patient survival and quality of life.
PDS01ADC Mechanism of Action Targets Immune Suppression and Potentiates Anti-Tumor Response
PDS01ADC works by directly targeting Interleukin-12 to the tumor site using the NHS76 antibody, aiming to boost the immune system’s ability to fight cancer while reducing common side effects. Early-stage results show the therapy can activate key immune cells—both T cells and natural killer cells—while reducing the impact of suppressive cells that often help tumors evade detection and destruction.
What’s Next? Potential for Further Development and Patient Impact
While these results are promising, it’s worth noting that the trial is ongoing and larger, randomized studies will be needed to confirm the benefit. Still, the jump in response and survival metrics is striking enough that observers may want to watch for expanded data and regulatory developments around PDS01ADC’s future. For now, the therapy stands out as a meaningful potential advance in one of oncology’s most challenging arenas.
Key Takeaway: A Step Forward in Immunotherapy for Colorectal Cancer
With robust trial data unlocking major gains in response and survival rates for a tough-to-treat cancer population, PDS01ADC offers hope for more targeted and resilient immunotherapy solutions. Investors, clinicians, and patients alike will be watching closely as this story unfolds—especially for those where standard treatments have fallen short.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI